This study provides an exhaustive analysis of the United States federal and North Carolina state Research and Development (R&D) tax credit requirements, evaluating administrative guidance, critical case law, and specific industrial evolution within Concord and Durham. It features ten targeted industry case studies demonstrating how regional enterprises navigate Internal Revenue Code (IRC) Section 41 eligibility and leverage state-level economic incentives for technological innovation. [cite: 1]

Part I: Concord, North Carolina – Industrial Evolution and Case Studies

Concord, the anchor city of Cabarrus County, provides a profound case study in industrial reinvention. Founded in 1796, Concord’s economy was dominated for over a century by the textile industry, catalyzed by the establishment of mills by John Odell, James Cannon, and Warren Coleman. Cannon Mills once stood as the world’s largest producer of fine towels and linens. However, as American textile manufacturing declined due to globalization, Concord’s civic leadership orchestrated a strategic pivot. Utilizing localized tax incentive packages, investments in the Concord-Padgett Regional Airport, and the exploitation of the I-85 logistics corridor, Concord transitioned its highly skilled blue-collar workforce into advanced manufacturing, motorsports, and food technology sectors. [cite: 1]

Case Study 1: Motorsports Engineering and Aerodynamic Dynamics

Industrial Development (Why and How): North Carolina’s motorsports legacy is famously intertwined with the prohibition era, where bootleggers illicitly modified their vehicles to outrun law enforcement, eventually transitioning these mechanical feats into organized stock car racing. Wilkes County served as a historical hub, but Concord emerged as the modern commercial epicenter of this $6 billion industry, housing Charlotte Motor Speedway and the R&D centers for elite NASCAR teams such as Hendrick Motorsports, Roush Fenway Racing, and Stewart-Haas Racing. The development of Windshear, a highly advanced wind-simulated testing facility in Concord, represents the pinnacle of localized aeronautical and aerodynamic engineering. [cite: 1]

Federal Eligibility (IRC § 41): Motorsports racing teams engage in continuous, high-stakes R&D to gain fractional competitive advantages. While the IRS previously denied deductions for amateur racing expenses (as seen in the 2023 Tax Court case involving attorney James Avery, where expenses were ruled non-deductible advertising under IRC § 162(a)), professional racing engineering heavily qualifies for the Section 41 credit. Eligible business components include designing advanced hybrid fuel energy systems, telemetry sensors, and new chassis geometries. Teams must engage in a process of experimentation—utilizing computational fluid dynamics (CFD) software and Concord’s wind tunnel testing facilities to evaluate the aerodynamic drag of newly fabricated exhaust headers or carbon-fiber splitters. Teams must ensure they are not merely tuning engines using known parameters (which would fail the technical uncertainty test), but rather designing mathematically novel components whose operational viability is unknown until physical track or wind-tunnel testing is complete. [cite: 1]

State Law Application: Under the North Carolina framework, while the state’s statutory R&D credit (Article 3F) sunset in 2015, pending legislation under Senate Bill 354 (The NC Breakthrough Act) would allow teams to capture up to 3.25% of these engineering costs. Furthermore, the immense capital required to build a facility like Windshear makes such entities prime candidates for the Job Development Investment Grant (JDIG), which provides cash grants based on the personal income tax withholdings of highly compensated aeronautical engineers. [cite: 1]

Case Study 2: Defense Contracting and Advanced Tactical Vehicles

Industrial Development (Why and How): Building on its heritage of heavy industrial infrastructure and a skilled mechanical workforce, Concord has successfully attracted major defense initiatives. A premier example is General Motors’ (GM) Defense division, which established a technical center in Concord specifically to leverage the region’s motorsports engineering talent, situating its division directly at the Hendrick Motorsports campus. GM Defense operates in Concord to innovate nine-passenger tactical vehicles designed to be air-dropped and deployed by the U.S. defense complex. [cite: 1]

Federal Eligibility (IRC § 41): Defense contracting operates at the absolute frontier of technological capability. Developing lightweight, blast-resistant armaments and advanced powertrain chassis systems inherently fulfills the IRC § 41 requirement for hard science engineering. However, the paramount hurdle for a Concord-based defense contractor is the “funded research” exclusion under IRC § 41(d)(4)(H). As demonstrated in Dynetics Inc. v. United States, engineering R&D performed under federal defense contracts is heavily scrutinized. If a defense agency pays the contractor under a cost-plus structure where financial risk is borne by the government, the credit is disallowed. To qualify, Concord defense contractors must structure their Department of Defense (DoD) contracts to include rigid milestone deliverables, warranty provisions, and firm-fixed-price terms. By retaining rights to the underlying intellectual property (e.g., dual-use technologies that can be sold to allied nations) and bearing the financial burden of prototype failure, the contractor can successfully claim the Qualified Research Expenses (QREs). [cite: 1]

State Law Application: Defense projects involving massive capital expenditures are highly eligible for the One North Carolina (OneNC) Fund. This discretionary grant assists with the physical upfitting of industrial hubs and infrastructure development, acting as a functional cash-flow substitute for the lack of an immediate state R&D tax offset. [cite: 1]

Case Study 3: Beverage Manufacturing and Packaging Automation

Industrial Development (Why and How): The Grounds at Concord, the site of a former Philip Morris cigarette manufacturing plant, symbolizes Concord’s economic rebirth. Capitalizing on available industrial acreage, extensive utility infrastructure, and highway connectivity, this site is now the home of “Project Aquamarine,” a staggering $1.7 billion vertically integrated beverage manufacturing hub. This campus combines Red Bull (beverage formulation), Rauch Fruchtsäfte (filling and distribution), and Ball Corporation (sustainable aluminum packaging manufacturing) into a 2-million-square-foot ecosystem. [cite: 1]

Federal Eligibility (IRC § 41): While food and beverage companies often mistakenly assume the R&D credit is reserved for software and pharmaceuticals, process engineering and automation scaling are heavily incentivized under federal law. Developing proprietary sustainable aluminum alloys that use less material while maintaining burst-pressure limits requires advanced metallurgy. Furthermore, scaling up an Austrian beverage formulation to run at a massive, unprecedented volume in a new facility involves technical uncertainty regarding fluid dynamics, pasteurization efficacy, and automated line speeds. The IRS dissects these process improvements closely. If a company merely installs standard, off-the-shelf canning equipment, it fails the Section 174 test. However, if their mechanical engineers must systematically design custom robotics and programmable logic controllers (PLCs) to handle a proprietary can shape or unprecedented throughput speeds, the labor and supply costs associated with designing and testing that custom line qualify as QREs. [cite: 1]

State Law Application: This specific tripartite development is a textbook execution of North Carolina’s modern incentive strategy. To secure this facility over competing states, the North Carolina Economic Investment Committee utilized massive Job Development Investment Grants (JDIG) tied to the creation of over 600 high-paying jobs, with a projected $20.8 million annual payroll impact. Should SB 354 become law, any future iterative packaging R&D conducted at The Grounds would generate additional statutory tax credits. [cite: 1]

Case Study 4: Advanced Plastics and Polymer Manufacturing

Industrial Development (Why and How): Concord’s transition from a textile-centric economy demanded a shift toward advanced material sciences. The existing infrastructure of mills and factories, combined with a workforce accustomed to shift-based manufacturing, provided fertile ground for the plastics industry. Today, plastics manufacturing stands as one of the thriving industries in Cabarrus County, supplying components for automotive, aerospace, and consumer goods sectors that require highly specialized material properties. [cite: 1]

Federal Eligibility (IRC § 41): Polymer manufacturing is fraught with technical uncertainty, specifically concerning thermal stability, tensile strength, and extrusion rates. When a Concord-based plastics manufacturer seeks to develop a new, lighter, and more heat-resistant polymer blend for an automotive client, they must experiment with various chemical catalysts, curing times, and mold designs. The systematic trial and error of these chemical formulations constitutes a valid process of experimentation. Under federal law, the wages of the chemical engineers, the cost of raw resins used during the testing phase (supplies), and third-party testing costs are eligible QREs. The manufacturer must ensure these expenses are properly capitalized and amortized over five years under the revised IRC § 174 rules before claiming the Section 41 credit. [cite: 1]

State Law Application: If SB 354 is enacted, this manufacturer could benefit from the proposed 3.25% general research credit. Furthermore, if the facility is located within a designated Eco-Industrial Park, they could potentially qualify for an unprecedented 35% state tax credit on their research expenses, heavily subsidizing the cost of sustainable polymer innovation. [cite: 1]

Case Study 5: Telecommunications and Broadcasting Equipment

Industrial Development (Why and How): Concord’s proximity to the rapidly expanding financial and technological hub of Charlotte naturally catalyzed the development of telecommunications and broadcasting equipment manufacturing. As data latency requirements for financial trading and digital broadcasting became more stringent, Concord offered the industrial space needed to prototype and manufacture complex hardware that could not be easily fabricated in dense urban centers. [cite: 1]

Federal Eligibility (IRC § 41): Hardware development in telecommunications involves resolving uncertainties related to signal multiplexing, radio frequency (RF) interference, and thermal management of high-density circuit boards. The prototyping phase is heavily reliant on engineering principles. However, companies in this sector must heed the warnings of the recent Phoenix Design Group, Inc. v. Commissioner (2024) Tax Court decision. The IRS will aggressively audit claims to ensure the firm is not simply applying known engineering principles to new physical layouts. The taxpayer must maintain contemporaneous, activity-level documentation proving that “substantially all” (at least 80%) of the activities involved in the prototyping phase constituted a true process of experimentation to resolve an objective technical uncertainty. [cite: 1]

State Law Application: Telecommunications firms often operate across state lines, making North Carolina’s corporate tax climate highly relevant. North Carolina has systematically reduced its corporate income tax rate from 6.9% in 2013 to 2% in 2026, with plans to reach 0% by 2030. While the lack of an immediate state R&D credit is a factor, the plummeting corporate tax rate, combined with potential JDIG awards for high-wage engineering jobs, creates a highly favorable net-tax environment for telecommunications R&D in Concord. [cite: 1]

Part II: Durham, North Carolina – Industrial Evolution and Case Studies

Durham’s economic trajectory represents one of the most successful planned economic transitions in global history. In the 1950s, North Carolina faced an economic crisis. Ranked 47th out of 48 states in per capita income, its economy was dangerously over-reliant on agriculture (tobacco), textiles, and furniture manufacturing, resulting in a massive “brain drain” of university graduates. In response, Governor Luther Hodges and visionary leaders conceptualized the Research Triangle Park (RTP). Geographically anchored by three tier-one research universities—Duke University in Durham, the University of North Carolina at Chapel Hill, and North Carolina State University in Raleigh—RTP was carved out of 7,000 acres of pine forests to serve as a collaborative engine for commercializing technology. Today, Durham County lies at the heart of a Metropolitan Statistical Area (MSA) ranked in the top 10 nationally for utility patents, boasting over 500 life science companies. [cite: 1]

Case Study 6: Contract Research Organizations (CROs) and Clinical Analytics

Industrial Development (Why and How): Durham is universally recognized as the birthplace of the Contract Research Organization (CRO) industry. This sector emerged in the 1980s from the need of pharmaceutical giants to outsource complex clinical trials, patient recruitment, and statistical analysis to specialized third parties. The industry was pioneered by Quintiles, founded in Chapel Hill in 1982 by UNC professors Dennis Gillings and Gary Koch, which later moved its global headquarters to Durham. Today, post-merger with IMS Health, the resulting entity—IQVIA—maintains its global headquarters in Durham, employing over 58,000 people globally and driving a sub-economy that includes seven of the world’s top ten global CROs. [cite: 1]

Federal Eligibility (IRC § 41): CROs occupy a highly complex position within the federal tax code because they conduct the physical labor of experimentation on behalf of other entities. The core service of a CRO—conducting Phase I-III clinical trials for a pharmaceutical sponsor—is fundamentally “funded research” under IRC § 41(d)(4)(H). The pharmaceutical sponsor retains the rights to the drug, and the CRO is paid for its services. Consequently, the CRO is legally barred from claiming the Section 41 credit for the primary clinical trial execution; the sponsor claims those expenses. [cite: 1]

However, Durham CROs are highly eligible for federal credits related to internal software and algorithmic improvements. As the clinical trial sector rapidly integrates Artificial Intelligence (AI) to identify potential drug therapies, accelerate trial enrollment, and automate data analytics, CROs must invest in their own proprietary software architectures. When a CRO like IQVIA develops a novel, cloud-based predictive algorithm to model patient drop-out rates in oncology trials, the software engineers and data scientists involved are performing qualified research. The technical uncertainty lies in the algorithmic architecture and machine learning efficacy, not the biological drug itself, thus fully qualifying under federal law. [cite: 1]

State Law Application: The economic footprint of CROs is massive. Because they act essentially as knowledge-based service exporters, they are prime targets for JDIG incentives when creating new data-center or analytical roles. Furthermore, if the NC Breakthrough Act (SB 354) is enacted, the AI-driven software development undertaken by CROs will fall under general qualified research categories, providing a critical tax reduction for their state corporate income tax footprint. [cite: 1]

Case Study 7: Biopharmaceutical Formulation and Manufacturing

Industrial Development (Why and How): Early RTP adopters like Burroughs-Wellcome (now part of GlaxoSmithKline) laid the foundation for Durham’s pharmaceutical dominance. The state doubled down on this sector by creating the North Carolina Biotechnology Center in 1984, the nation’s first state-sponsored initiative to develop biotechnology. Today, Durham hosts massive facilities for Merck, Biogen, and Eli Lilly, representing one of the highest concentrations of biomanufacturing in the world. [cite: 1]

Federal Eligibility (IRC § 41): Drug discovery and formulation inherently align with the highest ideals of IRC § 41. Designing new synthesis routes to improve the purity of active pharmaceutical ingredients (APIs) or determining the optimal nanoencapsulation delivery mechanism represents core technical uncertainty. Running comparative pathway trials, stability degradation testing, and Phase I-III clinical trials represent the purest form of the scientific method. However, companies must adhere strictly to the IRS Pharmaceutical Industry Research Credit Audit Technique Guide (ATG). The IRS ATG explicitly warns that Phase IV pharmacoeconomic studies (analyzing the cost-effectiveness of drugs) or post-launch marketing studies are disqualified, as they venture into prohibited “social sciences”. Life science firms may also stack the Section 41 credit with the Orphan Drug Credit (ODC) to maximize tax relief for therapies targeting rare diseases. [cite: 1]

State Law Application: Under the historical Article 3F, Durham pharmaceuticals benefited immensely from the 20% university research tier when partnering with Duke University or North Carolina Central University’s Julius L. Chambers Biomedical and Biotechnology Research Institute (JLC-BBRI). Under current law, expansion efforts (such as Eli Lilly’s recent $1 billion investments in the region) are frequently supported by bespoke JDIG grants. [cite: 1]

Case Study 8: Agricultural Biotechnology

Industrial Development (Why and How): Leveraging the presence of the National Institute of Environmental Health Sciences (NIEHS) and the Environmental Protection Agency (EPA) in RTP, Durham fostered a unique ecosystem for agricultural technology. The Research Triangle AgTech Cluster utilizes the region’s deep biological sciences talent to innovate in crop science, pest resistance, and sustainable farming methodologies. [cite: 1]

Federal Eligibility (IRC § 41): Agricultural biotechnology frequently involves genetic sequencing, phenotypic screening, and soil microbiome engineering. To claim the federal R&D credit, AgTech firms must ensure their research is firmly rooted in the hard sciences (biology, chemistry, genetics). The 2026 Tax Court case George v. Commissioner provides a critical framework here. In George, a poultry producer claimed credits for feed additives and disease mitigation. The court clarified that while farming can qualify, “there must be research and experimentation rooted in the hard sciences” and structured experiments to resolve scientific uncertainty. AgTech firms in Durham must maintain rigorous laboratory documentation proving they are genetically modifying organisms or developing novel biochemical pesticides, rather than merely engaging in routine agricultural husbandry. [cite: 1]

State Law Application: AgTech startups frequently rely on grant funding facilitated by the North Carolina Biotechnology Center. As these companies move from the laboratory toward commercialization and require physical greenhouse or manufacturing space, they become eligible for the OneNC Fund. The potential passage of SB 354 would provide these companies with a 3.25% baseline credit against their state tax liabilities. [cite: 1]

Case Study 9: Medical Devices and Diagnostics

Industrial Development (Why and How): The proximity of Duke University Medical Center and the extensive network of clinical trial infrastructure in Durham naturally bred a vibrant medical device and diagnostics sector. Companies like Corning Life Sciences and GRAIL have established significant footprints in Durham County to develop advanced diagnostic assays and surgical hardware. [cite: 1]

Federal Eligibility (IRC § 41): The design and development of new or improved medical devices, including diagnostic delivery systems, testing methods, and analytical procedures, are explicitly listed as qualifying activities. When a Durham company develops a novel microfluidic chip for early cancer detection, the mechanical engineering of the chip, the software engineering of the diagnostic interface, and the biological testing of the blood samples all represent distinct business components. The process of experimentation involves evaluating different polymer substrates for the chip and refining the diagnostic algorithms. The wages of the mechanical engineers, software developers, and QA/QC specialists involved in these iterations are fully eligible QREs. [cite: 1]

State Law Application: The medical device sector is highly capital-intensive during the prototyping phase. North Carolina’s elimination of tax credits in 2013 was offset by the creation of a highly favorable corporate tax environment. For diagnostic companies scaling their manufacturing operations, the state evaluates their potential to elevate the local average wage. Medical device manufacturing jobs typically exceed the Durham County average wage, automatically triggering eligibility for premium tiers of the JDIG program. [cite: 1]

Case Study 10: Gene Therapy and Advanced Therapeutics

Industrial Development (Why and How): Gene therapy represents the bleeding edge of the life sciences industry. Durham actively recruited companies like Beam Therapeutics, which focuses on precision genetic medicines, capitalizing on the highly specialized biomanufacturing workforce trained at institutions like the Biomanufacturing Research Institute and Technology Enterprise (BRITE). The region was recently named the nation’s top biomanufacturing hub by Jones Lang LaSalle (JLL) in Spring 2024, confirming its dominance in scaling complex therapeutics. [cite: 1]

Federal Eligibility (IRC § 41): Gene therapy involves an unprecedented level of technical uncertainty, specifically regarding viral vector engineering, CRISPR-Cas9 off-target effects, and cell line stability. Because these companies often operate at a massive loss during their initial years of FDA trials, they frequently have no federal income tax liability. Therefore, the QSB (Qualified Small Business) payroll tax election is critical. Firms with under $5 million in gross receipts and less than five years of gross receipts history can elect to apply up to $500,000 of their federal R&D tax credit against their payroll taxes (the employer’s portion of Social Security and Medicare). This provides an immediate, vital cash infusion to extend their operational runway. [cite: 1]

State Law Application: Gene therapy facilities require immense, specialized capital investments (e.g., cleanrooms, specialized bioreactors). North Carolina actively competes against hubs like Boston and San Francisco for these facilities. In instances like FUJIFILM Diosynth Biotechnologies (operating near the Triangle), the state deployed massive JDIG awards to secure the investment. If SB 354 is passed, the high capital burn rate of Durham biotech startups could generate vital non-dilutive tax capital through the state research credit, which can be carried forward for 15 years to offset future blockbuster drug revenues. [cite: 1]

Part III: The United States Federal R&D Tax Credit Legal Framework

The federal Research and Development tax credit, codified under Section 41 of the Internal Revenue Code (IRC § 41), was introduced to incentivize businesses to increase their investments in domestic research activities. The credit provides a dollar-for-dollar reduction in a company’s federal tax liability for QREs incurred within the United States. [cite: 1]

The Foundational Mechanics: Section 41 and the Four-Part Test

To qualify for the federal R&D tax credit, an organization’s activities must meet stringent criteria designed to distinguish routine engineering or standard software development from true technological innovation. This demarcation is governed by the statutory “Four-Part Test” outlined in IRC § 41(d). A taxpayer must prove that substantially all activities tied to a business component satisfy all four pillars. [cite: 1]

The Interplay Between IRC Section 174 and Section 41

A critical prerequisite for the Section 41 credit is the Section 174 test. Historically, IRC § 174 allowed taxpayers to immediately deduct research and experimental (R&E) expenditures in the year they were incurred. However, following the legislative changes implemented by the Tax Cuts and Jobs Act (TCJA) of 2017, effective for tax years beginning after December 31, 2021, taxpayers can no longer immediately expense these costs. Instead, they must capitalize and amortize domestic R&E expenditures over five years (and foreign R&E over 15 years). [cite: 1]

The IRS has issued extensive guidance, including Notice 2023-63, Notice 2024-12, and Revenue Procedure 2025-08, clarifying the amortization of specified research or experimental expenditures under Section 174. To claim the Section 41 credit, the expenses forming the basis of the claim must first qualify as Section 174 expenditures. The evolving compliance landscape demands that taxpayers meticulously bifurcate direct research costs from indirect developmental overhead. Small businesses receive retroactive relief options; they can amend their 2022–2024 returns to apply immediate expensing retroactively, with the window remaining open until the earlier of July 4, 2026, or the statute of limitations. [cite: 1]

Federal Administrative Guidance and Form 6765 Overhauls

The IRS has drastically increased its scrutiny of R&D tax credit claims, instituting enhanced reporting requirements to curb unsubstantiated applications. The primary vehicle for claiming the federal credit, Form 6765 (Credit for Increasing Research Activities), has undergone significant revisions. For tax years beginning in 2024 and 2025, the IRS introduced optional transitional reporting, but by 2026, the completion of a detailed “Section G” will be mandatory for most corporate taxpayers. [cite: 1]

Section G requires businesses to break down quantitative data and qualitative narratives by specific business components. Taxpayers must disclose specific qualitative descriptions of the information sought, the alternatives evaluated, and the precise process of experimentation undertaken for their largest projects. Qualified Small Businesses (QSBs) electing the reduced payroll tax credit, and taxpayers with QREs under $1.5 million and gross receipts under $50 million, may retain optional reporting status for Section G, providing a slight administrative reprieve for early-stage innovators in Concord and Durham. [cite: 1]

Part IV: North Carolina State R&D Tax Credit Laws and Economic Incentives

While the federal credit provides an overarching federal tax offset, state-level incentives play a monumental role in corporate site selection and capital allocation. North Carolina’s approach to R&D incentives has undergone significant structural transformations over the past decade. [cite: 1]

The Rise and Sunset of Article 3F

Historically, North Carolina offered one of the most robust state-level R&D incentives in the nation under Article 3F of the North Carolina General Statutes (N.C.G.S. § 105-129.50 et seq.). Filed via Form NC-478I, this credit provided a tiered incentive structure based on the type and volume of research. Taxpayers could claim a base rate of 1.25% for expenses up to $50 million, escalating to 3.25% for expenses exceeding $200 million. Furthermore, the state aggressively incentivized collaboration with academic institutions (crucial for Durham’s RTP ecosystem), offering a generous 20% credit for “North Carolina university research expenses”. [cite: 1]

However, prioritizing broad-based corporate income tax rate reductions over targeted tax credits, the North Carolina General Assembly allowed the Article 3F R&D tax credit to sunset on December 31, 2015. Consequently, no fixed, non-discretionary statutory R&D tax credit is available for activities conducted in North Carolina for the 2025 and 2026 tax years. Taxpayers who generated unused Article 3F credits prior to 2016 were permitted to carry those forward for up to 15 succeeding years. [cite: 1]

Note on the Interactive Digital Media Credit: North Carolina also housed an Interactive Digital Media Tax Credit under Article 3F, highly relevant to video game developers and digital media firms (such as Epic Games, based near the Triangle). While this specific credit has also sunset, the North Carolina Department of Revenue’s 2025 Economic Incentives Report shows that the state processed over $112,000 in carryforward claims for this credit during the 2024 calendar year, demonstrating the long-tail financial impact of legacy state credits. [cite: 1]

The Shift to Discretionary Grants: JDIG and OneNC

In lieu of a statutory R&D tax credit, the North Carolina Department of Commerce pivoted to discretionary, performance-based incentive programs to offset the costs of facility expansion and job creation. [cite: 1]

Pending Legislation: The NC Breakthrough Act (Senate Bill 354)

Recognizing the competitive disadvantage created by the lack of a statutory R&D credit—particularly against neighboring states with aggressive innovation incentives—the North Carolina legislature introduced Senate Bill 354 (The NC Breakthrough Act) in the 2025-2026 legislative session. [cite: 1]

If enacted, SB 354 would formally reenact a modified version of the Article 3F credit. The proposed legislation stipulates a reduced cap of 15% of total tax liability (down from the historical 50% cap) but retains the aggressive tiering strategy: 3.25% for small business research, 20% for university research expenses, and an innovative 35% credit for research conducted within designated Eco-Industrial Parks. Until SB 354 passes committee and is signed into law, companies operating in Concord and Durham must maximize federal IRC § 41 credits while negotiating discretionary state grants. [cite: 1]

Part V: Pivotal Tax Court Precedents Shaping R&D Audit Defense

The judicial landscape surrounding R&D tax credits is highly active. The IRS has adopted an aggressive litigation strategy targeting the “substantially all” requirement of the process of experimentation test and the legal parameters of funded research. Several recent cases fundamentally dictate how businesses must document their research. [cite: 1]

The Strict Scrutiny of the Process of Experimentation

In a landmark decision issued in late 2024, the United States Tax Court denied R&D tax credits to Phoenix Design Group (PDG), a multidisciplinary engineering firm specializing in mechanical, electrical, plumbing, and fire protection (MEPF) systems (Phoenix Design Group, Inc. v. Commissioner, T.C. Memo 2024-113). The IRS successfully disallowed credits across hundreds of projects, leading to a 20% accuracy-related penalty. [cite: 1]

The court’s analysis rested on the failure to prove objective technical uncertainty and a systematic process of experimentation. PDG presented evidence of the issues its engineers encountered (e.g., determining duct sizes based on airflow). However, the Tax Court explicitly ruled that performing standard calculations using available data to comply with building codes does not constitute an investigative activity. Because PDG already possessed the foundational engineering knowledge necessary to solve the problem, there was no true technical uncertainty. [cite: 1]

Similarly, in Little Sandy Coal Co., Inc. v. Commissioner (2023), the United States Court of Appeals for the Seventh Circuit affirmed a Tax Court ruling denying credits to a shipbuilding company that designed first-in-class vessels. The IRC requires that “substantially all” (at least 80%) of the activities tied to a business component must constitute a process of experimentation. Little Sandy Coal relied on post hoc, arbitrary estimates from management regarding the time employees spent on experimentation. The court ruled that novelty alone does not guarantee a tax credit; taxpayers must offer a “principled way” to determine the exact proportion of employee activities dedicated to experimentation, corroborated by contemporaneous documentation. [cite: 1]

The Nuances of Funded Research

Conversely, taxpayers have achieved defensive victories regarding the “funded research” exclusion. In Smith v. Commissioner (T.C. Memo 2024-110), the IRS moved for summary judgment against an architectural firm, arguing that the firm’s client contracts lacked specific language placing the firm at financial risk for failed research. The Tax Court denied the IRS’s motion, ruling that the presence of milestone payments—where the client is only obligated to pay if the taxpayer successfully satisfies designated milestones—inherently raises a genuine issue of material fact regarding whether the payment is contingent on success. A similar taxpayer victory regarding milestone payments was secured in early 2025 in System Technologies, Inc. v. Commissioner. [cite: 1]

The Hard Science Requirement

In the agricultural and biotech sectors, the 2026 Tax Court case George v. Commissioner clarified the boundaries of the “technological in nature” test. The case involved a large poultry producer that claimed significant R&D credits related to flock management techniques. The court allowed some credits but disallowed most, reinforcing that while agriculture is science-driven, the activities must be explicitly rooted in the hard sciences to resolve scientific uncertainty through structured experiments. [cite: 1]

Final Thoughts

The intersection of federal and state tax incentive law dictates the financial viability of America’s most innovative industries. As evidenced by the industrial hubs of Concord and Durham, North Carolina, maintaining competitive advantage requires a forensic understanding of both engineering capabilities and statutory tax law. The U.S. federal R&D tax credit remains a powerful financial tool, yet recent judicial precedents prove that the IRS will mercilessly disallow claims lacking meticulous, contemporaneous documentation. Simultaneously, the state-level incentive landscape remains dynamic; while North Carolina currently relies on discretionary grants like JDIG, the potential passage of the NC Breakthrough Act signals a potential return to aggressive, statutory R&D tax incentives. For corporations operating in motorsports, defense, biopharmaceuticals, and CRO sectors, harmonizing their technical operations with Section 174 capitalization rules and Section 41 substantiation requirements is a fundamental pillar of corporate strategy. [cite: 1]

The information in this study is current as of the date of publication, and is provided for information purposes only. Although we do our absolute best in our attempts to avoid errors, we cannot guarantee that errors are not present in this study. Please contact a Swanson Reed member of staff, or seek independent legal advice to further understand how this information applies to your circumstances. [cite: 1]